Cambridge Healthtech Institute’s Inaugural

Analytical Characterisation

Implementing New Technologies and Enhancing Analytical Strategies

March 24-25, 2020

 

Bioprocessing Summit Europe is excited to announce the launch of a new conference stream dedicated to the Analytical Characterisation of Biotherapeutics. We bring together leading scientists from the biopharmaceutical industry, academia and government to discuss novel characterisation methods, tools and technologies. Join us in Barcelona to improve your analytical strategies across all phases of development and production.

Preliminary Agenda

ADVANCED CHARACTERISATION TECHNOLOGIES

From Sample to Project Decision: Fully Automating MS Analytics of Next-Generation Protein Therapeutics

Miroslav Nikolov, PhD, Senior Scientist & Lab Head, Roche Pharma Research and Early Development (pRED)

The Delights of Diversity: Application of Native MS in a Biopharmaceutical Development Lab

Dan Bach Kristensen, PhD, Principal Scientist, Symphogen

Using Intrinsic Fluorescence Emission for Analysis of Cell Culture Media and Protein-Based Samples

Alan G. Ryder, PhD, Professor, Nanoscale Biophotonics Laboratory, National University of Ireland Galway

Talk Title to be Announced

Jonathan Bones, PhD, Principal Investigator, CCL, National Institute for Bioprocessing Research and Training (NIBRT)

REGULATORY CONSIDERATIONS

Genetic Stability Strategies for Developing Vaccines from Early Phase Development to a Commercial Product

Gerard Scheppink, Scientist, Product Characterisation/Analytical Development, Janssen Vaccines

New International Standards for New Challenges: Supporting Monoclonal Antibody Product Consistency in the Era of Biosimilars

Sandra Prior, PhD, Senior Scientist, National Institute for Biological Standards and Control (NIBSC, a centre of the MHRA)

Advanced Therapies: Ongoing Efforts in Setting Standard for Cell and Gene Therapies

Fouad Atouf, PhD, Vice President, Global Biologics, U.S. Pharmacopeia

IMPURITIES AND HOST CELL PROTEINS (HCPs)

Cell Population and Fingerprint Analysis for Decision Making along the Bioprocess Chain of ADCs and Biosimilars

Christoph Herwig, PhD, Head Research Area Biochemical Engineering, TU Vienna

 

HCP Immunoassays and Orthogonal Methods for Identification of HCP Impurities in Downstream SamplesCygnus_New

Eric Bishop Vice President of Research and Development Research and Development Cygnus Technologies

NOVEL PROTEINS

Analytical Characterisation of Novel High Potency Neurotoxin Therapeutics

David Spencer, Characterisation Manager, Ipsen Biopharm

Development of Bioassays for Bispecifics

Sachin Dubey, PhD, Deputy Director/Head, Formulation, Analytical and Drug Production Development, Glenmark Pharmaceuticals SA




For more details on the conference, please contact:
Gemma Smith

Senior Conference Director

Cambridge Healthtech Institute

Phone: +447754.518.131
Email: gsmith@cambridgeinnovationinstitute.com

 

For partnering and sponsorship information, please contact:

Companies A-K

Sherry Johnson

Business Development Manager

Cambridge Healthtech Institute

Phone: 781-972-1359
Email: sjohnson@cambridgeinnovationinstitute.com

 

Companies L-Z

Carolyn Cooke

Business Development Manager

Cambridge Healthtech Institute

Phone: 781-972-5412

Email: ccooke@healthtech.com